8FR7

A hinge glycan regulates spike bending and impacts coronavirus infectivity


Experimental Data Snapshot

  • Method: ELECTRON MICROSCOPY
  • Resolution: 3.39 Å
  • Aggregation State: PARTICLE 
  • Reconstruction Method: SINGLE PARTICLE 

wwPDB Validation   3D Report Full Report


This is version 1.1 of the entry. See complete history

Re-refinement Note

This entry reflects an alternative modeling of the original data in: 7kip


Literature

Structural insights into the modulation of coronavirus spike tilting and infectivity by hinge glycans.

Chmielewski, D.Wilson, E.A.Pintilie, G.Zhao, P.Chen, M.Schmid, M.F.Simmons, G.Wells, L.Jin, J.Singharoy, A.Chiu, W.

(2023) Nat Commun 14: 7175-7175

  • DOI: https://doi.org/10.1038/s41467-023-42836-9
  • Primary Citation of Related Structures:  
    8FR7

  • PubMed Abstract: 

    Coronavirus spike glycoproteins presented on the virion surface mediate receptor binding, and membrane fusion during virus entry and constitute the primary target for vaccine and drug development. How the structure dynamics of the full-length spikes incorporated in viral lipid envelope correlates with the virus infectivity remains poorly understood. Here we present structures and distributions of native spike conformations on vitrified human coronavirus NL63 (HCoV-NL63) virions without chemical fixation by cryogenic electron tomography (cryoET) and subtomogram averaging, along with site-specific glycan composition and occupancy determined by mass spectrometry. The higher oligomannose glycan shield on HCoV-NL63 spikes than on SARS-CoV-2 spikes correlates with stronger immune evasion of HCoV-NL63. Incorporation of cryoET-derived native spike conformations into all-atom molecular dynamic simulations elucidate the conformational landscape of the glycosylated, full-length spike that reveals a role of hinge glycans in modulating spike bending. We show that glycosylation at N1242 at the upper portion of the stalk is responsible for the extensive orientational freedom of the spike crown. Subsequent infectivity assays implicated involvement of N1242-glyan in virus entry. Our results suggest a potential therapeutic target site for HCoV-NL63.


  • Organizational Affiliation

    Biophysics Graduate Program, Stanford University, Stanford, CA, 94305, USA.


Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Spike glycoproteinA,
B [auth C],
C [auth B]
1,356Human coronavirus NL63Mutation(s): 0 
Gene Names: S2
UniProt
Find proteins for Q6Q1S2 (Human coronavirus NL63)
Explore Q6Q1S2 
Go to UniProtKB:  Q6Q1S2
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupQ6Q1S2
Glycosylation
Glycosylation Sites: 40
Sequence Annotations
Expand
  • Reference Sequence
Oligosaccharides

Help

Entity ID: 2
MoleculeChains Length2D Diagram Glycosylation3D Interactions
alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
AD [auth qA],
BA [auth b],
CB [auth 2],
D,
DB [auth 3],
AD [auth qA],
BA [auth b],
CB [auth 2],
D,
DB [auth 3],
EA [auth e],
EB [auth 4],
ED [auth uA],
GD [auth wA],
HB [auth 7],
HC [auth XA],
IA [auth i],
ID [auth yA],
KA [auth k],
KB [auth AA],
L,
MA [auth m],
MB [auth CA],
NC [auth dA],
OA [auth o],
OC [auth eA],
PB [auth FA],
PC [auth fA],
R,
S,
SC [auth iA],
T,
TB [auth JA],
VB [auth LA],
VC [auth lA],
W,
WA [auth w],
XB [auth NA],
XC [auth nA],
Z,
ZB [auth PA]
7N-Glycosylation
Glycosylation Resources
GlyTouCan:  G97423PY
GlyCosmos:  G97423PY
GlyGen:  G97423PY
Entity ID: 3
MoleculeChains Length2D Diagram Glycosylation3D Interactions
alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]alpha-D-mannopyranose-(1-6)-[alpha-D-mannopyranose-(1-3)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
AA [auth a],
AB [auth 0],
AC [auth QA],
BB [auth 1],
BD [auth rA],
AA [auth a],
AB [auth 0],
AC [auth QA],
BB [auth 1],
BD [auth rA],
CA [auth c],
CD [auth sA],
DC [auth TA],
DD [auth tA],
E,
EC [auth UA],
FA [auth f],
FB [auth 5],
FC [auth VA],
GA [auth g],
GB [auth 6],
GC [auth WA],
H,
HA [auth h],
HD [auth xA],
I,
IB [auth 8],
J,
JB [auth 9],
JC [auth ZA],
K,
KC [auth aA],
LA [auth l],
LB [auth BA],
LC [auth bA],
MC [auth cA],
N,
NB [auth DA],
O,
P,
PA [auth p],
Q,
QB [auth GA],
QC [auth gA],
RB [auth HA],
RC [auth hA],
SA [auth s],
SB [auth IA],
TA [auth t],
TC [auth jA],
U,
UA [auth u],
UC [auth kA],
V,
VA [auth v],
WB [auth MA],
WC [auth mA],
X,
Y,
YA [auth y],
YC [auth oA],
ZA [auth z]
7N-Glycosylation
Glycosylation Resources
GlyTouCan:  G55220VL
GlyCosmos:  G55220VL
GlyGen:  G55220VL
Entity ID: 4
MoleculeChains Length2D Diagram Glycosylation3D Interactions
alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-2)-[alpha-D-mannopyranose-(1-3)]alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranoseBC [auth RA],
F,
QA [auth q]
9N-Glycosylation
Entity ID: 5
MoleculeChains Length2D Diagram Glycosylation3D Interactions
beta-D-galactopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[beta-D-galactopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-2)-alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranoseCC [auth SA],
G,
RA [auth r]
9N-Glycosylation
Glycosylation Resources
GlyTouCan:  G36191CD
GlyCosmos:  G36191CD
GlyGen:  G36191CD
Entity ID: 6
MoleculeChains Length2D Diagram Glycosylation3D Interactions
alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-3)-alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranoseIC [auth YA],
M,
XA [auth x]
8N-Glycosylation
Glycosylation Resources
GlyTouCan:  G83582BK
GlyCosmos:  G83582BK
GlyGen:  G83582BK
Entity ID: 7
MoleculeChains Length2D Diagram Glycosylation3D Interactions
beta-D-galactopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-beta-D-galactopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-3)-alpha-D-mannopyranose-(1-6)-[alpha-L-fucopyranose-(1-6)-beta-D-galactopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-3)-alpha-D-mannopyranose-(1-3)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranoseDA [auth d],
OB [auth EA],
ZC [auth pA]
12N-Glycosylation
Entity ID: 8
MoleculeChains Length2D Diagram Glycosylation3D Interactions
alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranoseFD [auth vA],
JA [auth j],
UB [auth KA]
5N-Glycosylation
Glycosylation Resources
GlyTouCan:  G22768VO
GlyCosmos:  G22768VO
GlyGen:  G22768VO
Entity ID: 9
MoleculeChains Length2D Diagram Glycosylation3D Interactions
2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranoseJD [auth zA],
NA [auth n],
YB [auth OA]
2O-Glycosylation
Glycosylation Resources
GlyTouCan:  G42666HT
GlyCosmos:  G42666HT
GlyGen:  G42666HT
Entity ID: 10
MoleculeChains Length2D Diagram Glycosylation3D Interactions
alpha-D-mannopyranose-(1-4)-[alpha-D-mannopyranose-(1-6)]alpha-D-mannopyranose-(1-6)-[alpha-D-mannopyranose-(1-4)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
KD [auth 0A],
LD [auth 1A],
MD [auth 2A],
ND [auth 3A],
OD [auth 4A],
KD [auth 0A],
LD [auth 1A],
MD [auth 2A],
ND [auth 3A],
OD [auth 4A],
PD [auth 5A],
QD [auth 6A],
RD [auth 7A]
7N-Glycosylation
Experimental Data & Validation

Experimental Data

  • Method: ELECTRON MICROSCOPY
  • Resolution: 3.39 Å
  • Aggregation State: PARTICLE 
  • Reconstruction Method: SINGLE PARTICLE 
EM Software:
TaskSoftware PackageVersion
RECONSTRUCTIONcryoSPARC2
MODEL REFINEMENTPHENIX1.19

Structure Validation

View Full Validation Report



Entry History & Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
National Institutes of Health/National Institute of General Medical Sciences (NIH/NIGMS)United StatesR01AI148382
National Institutes of Health/National Institute of General Medical Sciences (NIH/NIGMS)United StatesS10OD021600
Department of Energy (DOE, United States)United States--
National Institutes of Health/National Eye Institute (NIH/NEI)United StatesR01GM080139
National Science Foundation (NSF, United States)United StatesMCB-1942763
National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS)United States1R01NS119505-01A1
National Science Foundation (NSF, United States)United StatesACI-1548562
Department of Energy (DOE, United States)United StatesDE-AC05-00OR22725

Revision History  (Full details and data files)

  • Version 1.0: 2023-10-04
    Type: Initial release
  • Version 1.1: 2024-10-16
    Changes: Database references, Structure summary